Compare Abbott Laboratories (ABT) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Canadian National Railway Co. — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Canadian National Railway Co. trades at $122.22 (market cap $74.49B). The key difference: Abbott Laboratories is far larger — about 2.2× Canadian National Railway Co.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CNI | |
|---|---|---|
Market Cap | $166.94B | $74.49B |
Sector | Health | Industrials |
52-Week High | $136.62 | $122.78 |
52-Week Low | $82.57 | $90.91 |
Enterprise Value | $193.69B | $89.95B |
Dividend Yield | 2.63% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CNI trades at $122.78, up 1.0% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS in line with expectations at $1.31, following beats in prior quarters, and maintains strong profitability with a 27.23% net income margin. Recent news highlights operational records in propane and grain shipments, alongside a new rail agreement for BHP's Jansen Potash Mine, supporting long-term growth.
The outlook is positive with a consensus price target of $142.33 implying 16% upside, though high valuation multiples and rising debt levels pose risks. Analyst sentiment is mixed with 35% buy ratings, but institutional interest remains steady. Key catalysts include Q2 2026 earnings on July 24, 2026, and execution on new logistics contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
